✦ LIBER ✦

Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor

✍ Scribed by Al-Ejeh, F.; Shi, W.; Miranda, M.; Simpson, P. T.; Vargas, A. C.; Song, S.; Wiegmans, A. P.; Swarbrick, A.; Welm, A. L.; Brown, M. P.; Chenevix-Trench, G.; Lakhani, S. R.; Khanna, K. K.

Book ID: 120191003
Publisher: The Society of Nuclear Medicine
Year: 2013
Tongue: English
Weight: 970 KB
Volume: 54
Category: Article
ISSN: 0161-5505
DOI: 10.2967/jnumed.112.111534

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of the oral PARP inhibitor

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

✍ Dent, Rebecca A; Lindeman, Geoffrey J; Clemons, Mark; Wildiers, Hans; Chan, Arle 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 207 KB

189 Preclinical activity of the poly (AD

189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

✍ N. Nechiporchik; K. Lieb; L. Marquette; L. Polin; G.J. Peters; A. Chen; S.P. Eth 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB